Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2013 Q1- Text added to 2013 Q2
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
New words:
alleging, appeal, artificially, attention, blind, blinded, breach, brought, California, clear, complaint, consultant, counsel, Court, CSM, damage, detailed, dismissal, District, entry, extinguishment, false, IIb, incremental, insufficient, merit, Mine, misleading, model, molecular, monetary, negligence, Panel, path, plaintiff, promulgated, purported, pursue, pursuing, pursuit, Qualification, relief, reminded, repaid, reputation, routine, se, settlement, Similarly, source, split, thereon, thereunder, tied, unamortized, unfavorable, unspecified, valuation, vigorously, violated, yield
Removed:
added, advancement, afforded, AG, agreed, alpha, antiviral, ArQule, assuming, Biolex, BioPharma, Biotech, boceprevir, Chugai, cornerstone, CureTech, cyclophilin, Daiichi, Danoprevir, Debiopharm, depression, Digna, discontinue, Filibuvir, Flamel, Gilead, Globeimmune, GS, HanAll, Hanferon, hematologic, Idera, immunomodulatory, improvement, INCIVEKTM, Infergen, Inhibitex, Intercell, interferon, internally, Johnson, July, lambda, Medivir, mericitabine, nitazoxanide, nucleoside, nucleotide, obligated, pegylated, polymerase, presently, protease, recently, ribavirin, Roche, Romark, Sankyo, telaprevir, TEVA, tolerate, toxicity, Transgene, uncommon, USP, Vertex, XL
Valuein 2013 Q1 filing- Value in 2013 Q2 filing
Original filings
Filing view